Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging

Min Young Yoon¹, Juhyun Park¹, Jeong Yeon Cho², Chang Wook Jeong¹, Ja Hyeon Ku¹, Hyeon Hoe Kim¹, Cheol Kwak¹

Departments of ¹Urology and ²Radiology, Seoul National University Hospital, Seoul, Korea

Purpose: We aimed to investigate whether the apparent diffusion coefficient (ADC) value in diffusion-weighted magnetic resonance imaging predicts the prognoses of patients with high-risk prostate cancer.

Materials and Methods: A total of 157 patients with high-risk prostate cancer (based on D’Amico’s criteria) were included in the analysis. Patients underwent preoperative 3.0 Tesla magnetic resonance imaging within 2 months before radical prostatectomy. Those who received neoadjuvant hormone therapy (33 persons) or radiation therapy (18 persons) were excluded. The ADC of the tumor calculated from 2 b-values (0 and 1,000 s/mm²) was measured. Areas under receiver operating characteristics curves were calculated to maximize the accuracy of the ADC value. Based on the obtained cutoff value, the patients were stratified into 2 groups: Group A consisted of patients with ADC values <746×10⁻⁶ mm²/s and group B comprised those with ADC values ≥746×10⁻⁶ mm²/s.

Results: Group A showed higher rate of lymph positive and biochemical recurrence (BCR) rates than group B. Kaplan-Meier analysis showed that the BCR-free survival rate of group A was much lower than that of group B (p<0.001). On Cox proportional regression analyses, ADC group A (hazard ratio [HR], 3.238, p=0.002) and pathologic lymph node positive (HR, 2.242; p=0.009) were independent predictors of BCR.

Conclusions: In patients with high-risk prostate cancer, ADC value is significantly associated with BCR-free survival. Therefore, the ADC value is a useful tool for predicting the prognoses of these high-risk patients.

Keywords: Magnetic resonance imaging; Prognosis; Prostate neoplasms; Recurrence

INTRODUCTION

The incidence of prostate cancer is increasing in Korea as well as globally. In 2013, the incidence rate of this disease in Korea was 37.6 per 100,000 persons, which represented an almost 5-fold increase over the rate reported in 2000 (7.2 per 100,000 persons) [1,2]. In that year, prostate cancer was the fourth most common malignancy in the population aged ≥65 years [1,2].

Magnetic resonance imaging (MRI) has proven to be effective for the detection, treatment exploration, and follow-up examination of prostate cancer [3]. In particular,
diffusion-weighted MRI (DW-MRI), which is based on the mobility of hydrogen protons in water, has gained attention owing to its ability to differentiate aggressive tumor types with higher Gleason scores from indolent lesions [4-10]. The apparent diffusion coefficient (ADC) is a measure of the average rate of a hydrogen proton’s movement (mm/s$^2$). Therefore, the ADC decreases as tissue cells become denser. A tumor typically demonstrates denser cell distribution and sparser extracellular space; therefore, the ADC value is lower in prostate cancer tissue [3].

It has been reported that patients who meet the same high-risk prostate cancer criteria still exhibit a broad range of outcomes. Meanwhile, several recent studies have shown an inverse association between ADC values and Gleason scores, as well as other adverse prostate cancer pathologic features [5,9-13]. However, to the best of our knowledge, no study has examined the relationship between ADC values and the prognosis of high-risk prostate cancer in particular. In this study, we investigated the relationship between ADC values and the prognoses of patients who met the D’Amico criteria for high-risk prostate tumors.

**MATERIALS AND METHODS**

1. **Patients**

   Between January 2007 and December 2013, 1,844 prostate cancer patients underwent radical prostatectomy at our center. From among these patients, we included 549 who preoperatively underwent 3-T DW-MRI. After excluding patients who received neoadjuvant hormone therapy (33 persons) or radiation therapy (18 persons), we ultimately selected 157 patients who were determined to be at high risk according to D’Amico’s criteria for prostate cancer (i.e., those with a biopsy Gleason score≥8, preoperative prostate-specific antigen [PSA] level≥20 ng/mL, or clinical stage≥T2c). The study protocol was approved by the Seoul National University Hospital Institutional Review Board (approval number: 1511-034-718); the requirement for informed consent was waived owing to the retrospective nature of the study.

2. **MRI techniques**

   We used 3.0 Tesla (3-T) MRI systems (Magnetom Verio and Magnetom Trio, Siemens Healthcare, Munich, Germany) without an endorectal probe. Before undergoing MRI, patients were injected with 20-mg butylscopolamine (Buscopan, Boehringer-Ingelheim, Ingelheim, Germany) intramuscularly to suppress bowel peristalsis. We acquired multplanar (axial, coronal, and sagittal) T2-weighted images with the following parameters: repetition time range/echo time range, 3,400–4,500/100–140; slice thickness, 3 mm; interslice gap, 0.3 mm; matrix, 512×318; field of view, 22 cm; number of signals acquired, 2; and parallel imaging acceleration factor, 2. We performed axial fat-suppressed single-shot echoplanar diffusion-weighted imaging with the following parameters: repetition time range/echo time, 3,400–4,500/100–140; slice thickness, 3.5 mm; no interslice gap; matrix, 192×192; field of view, 30 cm; number of signals acquired, 6; parallel imaging acceleration factor, 2; and b-values, 0 and 1,000 s/mm$^2$ [14]. Because our hospital only had MRI equipment capable of producing images with b-values ≤1,000 s/mm$^2$ between 2007 and 2013, we were unable to use b-values >1,400 as recommended by the new Prostate Imaging Reporting and Data System guidelines (ver. 2).

3. **Acquisition of ADC values**

   One uroradiologist examined the patients’ ADC maps.
First, the darkest areas of the pertinent histopathologic lesions were identified (Fig. 1) [15]. Next, lesions of similar or larger sizes were evaluated to obtain the mean ADC values. The diffusion-encoding gradients were applied as a bipolar pair at b-values of 0 and 1,000 s/mm$^2$; the ADC maps were automatically generated on a pixel-by-pixel basis [16-19].

4. Statistical analysis

The area under the receiver operating characteristics curve was used to determine the optimal ADC cutoff. We used the t-test, chi-square test, and Cox progression model to describe the relationships between the variables. The relation between the ADC$_{mean}$ and the biochemical recurrence (BCR)-free survival rate was assessed using Kaplan-Meier analysis. Univariate and multivariate Cox proportional regression analyses were performed for the covariates of age, PSA, ADC value, pathologic Gleason score, and pathologic stage. A p-value of <0.05 was considered statistically significant; the IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used to analyze the data.

---

1. Patient demographics

A total of 157 patients underwent analysis for age, body mass index (BMI), prostate volume, preoperative PSA level, biopsy Gleason score, pathologic Gleason score, clinical stage, pathologic stage, positive surgical margin, BCR, and postoperative follow-up period (Table 1). The mean patient age was 66.9 years, and the mean BMI was 24.2 kg/m$^2$. The median prostate volume was 43.1 mL, while the mean PSA level was 24.4 ng/mL. The incidence of clinical stage ≤T2 was 79.6% while that of pathologic stage ≤T2 was 42.7%. A biopsy Gleason score ≥8 was recorded in 726% of the patients, and a pathologic Gleason score ≥8 was found in 30.6%. The mean postoperative follow-up period was 33.8 months. The total BCR rate was 43.9%.

2. Determination of the ADC cutoff and grouping of patients

The patients showed a normal distribution curve, and the average ADC value was 677.3×10$^{-6}$ mm$^2$/s (standard deviation, 184.0×10$^{-6}$ mm$^2$/s). The area under the receiver operating characteristics curve was used to determine the optimal ADC cutoff, which was 746×10$^{-6}$ mm$^2$/s. Patients with ADC values <746×10$^{-6}$ mm$^2$/s were classified as group A, and those with ADC values ≥746×10$^{-6}$ mm$^2$/s were classified as group B. The average ADC value for group A was 581×10$^{-6}$ mm$^2$/s, while for group B it was 894×10$^{-6}$ mm$^2$/s. Group A included 110 patients (70.1%), and group B included 47 patients (29.9%).

---

Table 1. Patient demographics

| Demographic                    | Total | Group A           | Group B           | p-value |
|--------------------------------|-------|------------------|------------------|---------|
| No. of patients                | 157   | 110 (70.1)       | 47 (29.9)        |         |
| Age (y)                        |       | 66.9±6.2         | 67.0±6.4         | 0.745   |
| Body mass index (kg/m$^2$)     |       | 24.2±2.9         | 24.3±2.9         | 0.518   |
| Preoperative PSA (ng/mL)       |       | 24.4±29.4        | 25.0±25.9        | 0.716   |
| Prostate volume (mL)           |       | 43.1±17.4        | 42.8±17.6        | 0.818   |
| Preoperative ADC (10$^{-6}$ mm$^2$/s) | | 675±184          | 581±116          | <0.001  |
| Biopsy Gleason score ≤7        | 43    | 27.4             | 30.9             | 0.130   |
| ≥8                             | 114   | 72.6             | 69.1             | 0.802   |
| Clinical T stage ≤T2           | 125   | 79.6             | 79.1             | 0.604   |
| ≥T3                            | 32    | 20.4             | 20.9             | 0.082   |
| Pathologic Gleason score ≤7    | 109   | 69.4             | 68.2             | 0.082   |
| ≥8                             | 48    | 30.6             | 31.8             | 0.581   |
| Pathologic T stage ≤T2         | 67    | 42.7             | 38.2             | 0.041   |
| ≥T3                            | 90    | 57.3             | 61.8             | 0.021   |
| Positive surgical margin       | 73    | 46.5             | 51.8             |         |
| Pathologic LN positive         | 22    | 14.0             | 18.2             |         |
| Follow-up duration (mo)        | 33.8  | 12.0             | 10.9             |         |
| BCR                            | 69    | 43.9             | 55.5             |         |

Values are presented as number (%) or mean±standard deviation.

Group A, patients with ADC values <746×10$^{-6}$ mm$^2$/s; group B, patients with ADC values ≥746×10$^{-6}$ mm$^2$/s; PSA, prostate-specific antigen; ADC, apparent diffusion coefficient; LN, lymph node; BCR, biochemical recurrence.
operating characteristics curve was 0.691 (95% confidential interval [CI], 0.612–0.762), the sensitivity was 89.86 (95% CI, 80.2–95.8), and the specificity was 43.18 (95% CI, 32.7–54.2). The cutoff value of $746 \times 10^{-6}$ mm$^2$/s was chosen to maximize the discriminatory ability related to sensitivity and specificity (Fig. 2) [20]. Next, the patients were stratified into 2 groups according to this cutoff value; Group A comprised patients with measured tumor ADC values < $746 \times 10^{-6}$ mm$^2$/s while group B patients had measured tumor ADC values $\geq 746 \times 10^{-6}$ mm$^2$/s. The data were comparatively analyzed in terms of age, PSA level, ADC value, pathologic Gleason score, pathologic stage, positive surgical margin, and BCR.

Various factors were compared between groups A and B (Table 1). Pathologic lymph node positive was recorded in 18.2% of the patients in group A and 4.3% of those in group B ($p=0.021$). A positive surgical margin was detected in 51.8% of the patients in group A and 34.0% of those in group B ($p=0.041$). BCR was observed in 55.5% of the patients in group A and 17.0% of those in group B ($p<0.001$).

3. Relationship between ADC$_{\text{mean}}$ and BCR-free survival rate

On Kaplan-Meier analysis, there was a significant difference in the BCR-free survival rate according to the ADC$_{\text{mean}}$ ($p<0.001$) (Fig. 3A). There is no decrease in the BCR-free survival rate of group B 30 months after the prostatectomy, whereas that of group A continuously decreased. By 50-month postradical prostatectomy, the BCR-free survival rate of group B was approximately 80% in group A, it was approximately 20%. Additionally, we analyzed the significance of ADC$_{\text{mean}}$ regarding BCR-free survival according to pathologic Gleason score ($\leq 7$ vs. $\geq 8$) and pathologic T stage ($\leq T2$ vs. $\geq T3$) through subgroup analyses. As shown Fig. 3, group A also had significantly worse BCR among the subgroup of patients with pathologic Gleason score $\leq 7$ ($p=0.002$) (Fig. 3B) and those with pathologic T stage $\leq T2$ ($p=0.001$) (Fig. 3D). However, such phenomenon was not observed among the subgroup of patients with Gleason score $\geq 8$ ($p=0.051$) (Fig. 3C) or those with pathologic T stage $\geq T3$ ($p=0.119$) (Fig. 3E).

4. Correlation between prostate cancer-associated covariates and BCR

On univariate Cox proportional regression analysis, group A (HR, 3.744; $p<0.001$), pathologic $\geq T3$ disease (HR, 1.836; $p=0.018$), and pathologic lymph node positive (HR, 2.563; $p<0.001$) were significantly correlated with BCR, respectively. Multivariate analysis showed the same correlation of group A (HR, 3.238; $p=0.002$) and pathologic lymph node positive (HR, 2.242; $p=0.009$) (HRs, 1.728 and 1.787; $p=0.001$ and $p=0.034$, respectively). Age, PSA level, pathologic Gleason score $\geq 8$, pathologic $\geq T3$ disease, and surgical margin positivity were not significantly correlated with BCR (Table 2).

**DISCUSSION**

In this study, we investigated only patients with high-risk prostate cancer (PSA $\geq 20$ ng/mL or a preoperative biopsy Gleason score $\geq 8$), and found that ADC$_{\text{mean}}$ is significantly associated with BCR-free survival in this specific patient subset. MRI technology is continuously evolving, and its more extensive use in clinical trials and practice has shown to improve prostate cancer diagnosis and treatment planning [3]. Additionally, newly developed 3-T MRI systems have provided several useful diagnostic measures, such as the ADC value, for evaluating prostate cancer [4-6,8-10]. Verma et al. [4] claim that ADC values might help to predict the incidence of prostate cancer, especially for tumors located in the peripheral zone [8]. They also reported that the ADC values were negatively correlated with the postsurgical Gleason grade in patients with prostate cancer ($r=-0.39$ for peripheral zone cancer). Furthermore, both ADC values and tumor volumes were found to significantly predict tumor aggressiveness, specifically in the peripheral
zone (area under the curve, 0.78). Similarly, we found that low ADC values were significantly correlated with BCR.

Hambrock et al. [5] reported that the ADC values obtained using 3-T MRI showed an inverse relationship with the Gleason grade in peripheral zone prostate cancer [9,10]. Moreover, a high discriminatory performance was attained when differentiating between low-, intermediate-, and high-grade cancer. However, because our cohort comprised only high-risk prostate cancer patients, a pathologic Gleason score ≥8 had no significant correlations with the BCR.

Both the tumor volume and true diffusion ADC were reported as significant and independent predictors of histologic progression by van As et al. [7] This was consistent with our findings that pathologic stage ≥T3 disease and low ADC values were significant predictors of progression as determined by BCR on univariate Cox regression analyses. Furthermore, ADCmean <746×10⁻⁶ mm²/s measured on the ADC maps correlated with early BCR on Kaplan-Meier

Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmean values among the total subjects (A) and among the 4 different subgroups: pathologic Gleason score ≤7 (B), pathologic Gleason score ≥8 (C), pathologic stage ≤ T2 (D), and pathologic stage ≥ T3 (E). Group A, patients with ADC values <746×10⁻⁶ mm²/s; group B, patients with ADC values ≥746×10⁻⁶ mm²/s; ADC, apparent diffusion coefficient.
ADC in patients with high-risk prostate cancer

As mentioned in the introduction, the ADC decreases as tissue cells become denser. A tumor typically demonstrates denser cell distribution and sparser extracellular space; therefore, the ADC value is lower in prostate cancer tissue. Denser tumor cellularity may be related with tumor stage and aggressiveness. So ADC value can be used as surrogate marker of tumor biology.

Because low risk patient group of prostate cancer has higher ADC value than high risk patient group of prostate cancer, it is more difficult to detect cancer and estimate prognosis in low risk patient group of prostate cancer than high risk patient group of prostate cancer. So we chose the high risk patient group of prostate cancer for analysis.

The reason that the PSA level and pathologic Gleason score≥8 did not affect BCR is that our inclusion criteria encompassed patients with PSA≥20 ng/mL or a preoperative biopsy Gleason score≥8; hence, our study was already aimed towards patients with advanced disease. We selected the 3-T MRI protocol because of higher magnetic field homogeneity and future applicability. Kitajima et al. [21] claim said that 3-T MRI may detect prostate cancer more effectively than 1.5 T MRI because of higher signal-noise ratio, faster acquisition time, and higher spatial resolution. Positioning lesions with low ADC values was difficult owing to the ADC readers’ subjective differences, which resulted in subtle variations in the reading of these values; however, the range of ADC reading variations was small. Automated reading of ADC values using computer software would be helpful for future studies.

One abnormal result which we found is the discrepancy between biopsy Gleason score≥8 (72.6%) and pathologic Gleason score≥8 (30.6%). Not only group A (ADC<746×10⁻⁶ mm²/s) but also group B (ADC≥746×10⁻⁶ mm²/s) have lower pathologic Gleason score≥8 than biopsy Gleason score≥8 (Table 1). We discussed this down grading with Department of Pathology in Seoul National University Hospital, but could not find causes. So we need to investigate this problem further.

One limitation of our study is its retrospective nature; selection bias was possible because we only included patients who initially underwent prostatectomy. Additionally, we used the average ADC value, whereas other studies reported the minimum, 10th, and/or 25th percentiles as well as other metrics such as skewness and kurtosis. Inability to use b-values other than 0 and 1,000 s/mm² is also a limitation of our study; moreover, translating our specific cutoff value across different scanners and protocols is also difficult. Therefore, devising a new universal cutoff value is warranted. When we tried propensity score matching about relationship between pathologic lymph node positive and BCR-free survival rate, we could not secure statistic significance because of small number of patients. This means that we cannot exclude confounding factor except ADC value. Nevertheless, our research has important clinical implications in that the ADCmean can predict the prognoses of patients with high-risk prostate cancer.

### Table 2. Univariate and multivariate cox-proportional regression analyses for the factors predicting biochemical recurrence after radical prostatectomy

| Variable                  | Univariate HR (95% CI) p-value | Multivariate HR (95% CI) p-value |
|---------------------------|--------------------------------|----------------------------------|
| Age                       | 0.989 (0.951–1.028) 0.568       | 0.974 (0.938–1.012) 0.175         |
| Preoperative PSA           | 0.998 (0.989–1.006) 0.573       | 0.992 (0.982–1.003) 0.147         |
| ADC group                  |                                |                                  |
| Group B                    | 3.744 (1.785–7.851) <0.001      | 3.238 (1.516–6.915) 0.002         |
| Group A                    | 1                              | 1                                |
| Pathologic GS              |                                |                                  |
| ≤7                        | 1.204 (0.735–1.973) 0.461       | 0.972 (0.584–1.621) 0.915         |
| ≥8                        | 1                              | 1                                |
| Pathologic stage           |                                |                                  |
| ≤T2                       | 1.836 (1.111–3.034) 0.018       | 1.542 (0.885–2.686) 0.126         |
| ≥T3                       | 1.583 (0.981–2.552) 0.060       | 1.108 (0.663–1.850) 0.696         |
| Positive surgical margin   | 2.563 (1.477–4.449) 0.001       | 2.242 (1.228–4.091) 0.009         |
| Pathologic LN positive     |                                |                                  |

Table A, patients with ADC values <746×10⁻⁶ mm²/s; group B, patients with ADC values ≥746×10⁻⁶ mm²/s.; ADC, apparent diffusion coefficient; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; ADC, apparent diffusion coefficient; GS, Gleason score; LN, lymph node.
CONCLUSIONS

In patients with high-risk prostate cancer, ADCmean is significantly associated with BCR-free survival. Therefore, the ADC value is a useful tool for predicting the prognoses of patients with high-risk prostate cancer. DW-MRI ADC may better differentiate aggressive prostate cancers from indolent tumors. 3-T DW-MRI ADC may therefore stratify high-risk patients according to prognosis.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01006813). This study was also funded by the CJ HealthCare, Korea (No. 0620154090). The funders had no role in study design, experiments, data collection and analysis, preparation of the manuscript, or the decision to publish.

REFERENCES

1. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41.
2. Yoon SJ, Bae SC, Lee SI, Chang H, Jo HS, Sung JH, et al. Measuring the burden of disease in Korea. J Korean Med Sci 2007;22:518-23.
3. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962-77.
4. Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011;196:374-81.
5. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259:453-61.
6. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Futterer JJ, van Oort IM, van Basten JP, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol 2012;47:153-8.
7. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009;56:981-7.
8. Epstein JJ, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
9. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
10. Brachman DG, Thomas T, Hilde J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111-7.
11. Donati OF, Afao A, Vargas HA, Mazahery Y, Zheng J, Moskwitz CS, et al. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res 2014;20:3705-11.
12. Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012;109:1636-47.
13. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007;357:2696-705.
14. Woo S, Cho JY, Kim SY, Kim SH. Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 2015;204:W168-75.
15. Donati OF, Mazaheri Y, Afao A, Vargas HA, Zheng J, Moskwitz CS, et al. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 2014;271:143-52.
16. Jeong CW, Park YH, Hwang SI, Lee S, Jeong SJ, Hong SK, et al. The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int 2014;2:169-75.
17. Borren A, Moman MR, Groenendaal G, Boeken Kruger AE, van Diest PJ, van der Groep P, et al. Why prostate tumour delineation based on apparent diffusion coefficient is challenging: an exploration of the tissue microanatomy. Acta Oncol 2013;52:1629-36.
18. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE In-
vestigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-4.
19. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866-71.
20. Nagayama M, Watanabe Y, Terai A, Araki T, Notohara K, Okumura A, et al. Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer. Jpn J Radiol 2011;29:488-94.
21. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010;31:625-31.

EDITORIAL COMMENT

When we investigate differences in the prognosis of prostate cancer (PCa) between the 2 groups, besides the specific variable under study, other variables should be held constant, such as age, pathologic stage, and surgical margin status. The study by Yoon et al. [1] included 157 men with high-risk PCa who underwent radical prostatectomy after preoperative 3.0 Tesla magnetic resonance imaging (MRI) to determine the apparent diffusion coefficient (ADC) value. The researchers stratified the patients into 2 groups based on the ADC value in diffusion-weighted MRI. The study results showed higher rates of biochemical recurrence (BCR) in group A (ADC values <746×10^{-6} mm²/s) than in group B (ADC values ≥746×10^{-6} mm²/s). In addition, the researchers showed that group A had shorter BCR-free survival than did group B. However, group A included significantly more patients with lymph node invasion than did group B (Table 1 in Ref. [1]). Moreover, lymph node involvement was related with the BCR rate in the multivariate analysis. Thus, it is possible that lymph node involvement affected the prognosis of group A. Additionally, the ADC did not appear to have diagnostic value in the subgroup of patients with a Gleason score ≥8 (Fig. 3C in Ref. [1]) or in those with pathologic T stage ≥T3 (Fig. 3E in Ref. [1]).

PCa patients with clinical T3 disease or a Gleason score ≥8 or prostate-specific antigen >20 ng/mL are lumped together as having “high-risk” PCa, but they represent individual subgroups with different long-term oncologic outcomes [2]. In my opinion, before generalizing the results of the study by Yoon et al. [1], we need to specify these results for selected groups such as patients with a Gleason score <8 and pathologic T stage <T3. Hopefully, MRI technology will continue to improve to provide more accurate information for men with high-risk PCa.

CONFLICTS OF INTEREST

The author has nothing to disclose.

Jae Young Park
Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
E-mail: jaeyoungpark@korea.ac.kr

REFERENCES

1. Yoon MY, Park J, Cho JY, Jeong CW, Ku JH, Kim HH, et al. Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging. Investig Clin Urol 2017;58:12-9.
2. Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 2015;67:157-64.